The Healing Power of Botanical Therapeutics®


Herborium Group Preliminary 3rd Quarter Revenues show the record results. 2012 expected to end with strong financial results and record demand for HBRM products.

HERBORIUM GROUP, INC. COMMENCES REPURCHASING OF UP TO 100 MILLION SHARES OF ITS COMMON STOCK; 1150 of 2300 cases of Kamasutra™ lands in the USA today for immediate distribution

Press Release: Herborium Group, Inc. — Wed, Sep 19, 2012 5:00 AM EDT

FORT LEE, N.J., Sept. 19, 2012 /PRNewswire/ -- Herborium Group, Inc., (OTC Pink: HBRM), a Botanical Therapeutics® Company is pleased to announce that it has now commenced the repurchase of the Company's common shares . "We have now commenced our share buyback program which was announced on April 23, 2012. After review of our strong 3rd quarter revenues along with the rapidly increasing orders of AcnEase® and enthusiastic response to Kamasutra™ Spirit with our proprietary blend of exotic herbs, that are being processed for the 4th quarter we have decided that this gives us the financial opportunity to repurchase up to 100 million shares which process begun and will continue in this 4th Quarter to the end of 2012," stated Dr. Agnes P. Olszewski Chairwoman and CEO of Herborium. "Thanks to our very successful social media marketing strategy, a demand for AcnEase®, our unique all botanical acne treatment targeting over 120 million acne sufferers in the US and Europe, has been up for the 3rd consecutive Quarter with sales up over 20% yet again. The Company is anticipating to continue its growth in 4th Quarter making 2012 not only a very successful sales year, but the beginning of a new phase for the future. The 4Th Quarter of 2012 is also the time when the Company is to launch its unique Botanical Therapeutics® for Sexual Health for Women and Men, and its all botanical ingredients based healthy Energy formula. Together with an introduction of Kamasutra™ we are indeed on the road to build a much larger Herborium as we enter new avenues for the use of our product," concluded Dr. Olszewski.

With the anticipated continuous growth that the Company expects to capture in 2013 financial projections forecast Herborium is currently in the process of taking steps of becoming a fully reporting, audited Public Entity at some point in 2013.

About Herborium Group, Inc.

Herborium Group, Inc., a Botanical Therapeutics® company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company uses clinical validation to establish and maintain a differential advantage. The company sells its products in the US and Europe. For more information, please visit and

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. The Company urges investors to review the risks and uncertainties contained within its filings with the OTC Markets and/or Securities and Exchange Commission.



Information provided on about medical conditions, symptoms, and related products is not intended to be a substitute for professional medical advice. Visitors to this site should not use this information to diagnose or treat a health problem, symptom, concern or disease without consulting with their individual qualified healthcare provider. Statements contained on this website have not been evaluated by the FDA. Herborium products are not intended to diagnose, heal, cure or prevent disease.